We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Neurana Pharmaceuticals has completed enrollment in the "STAR Study," a Phase 2 dose ranging study of tolperisone in acute muscle spasms of the back in over 400 patients.
Enrollment for health insurance under the Affordable Care Act is down with just days left to sign up, according to the U.S. Centers for Medicare & Medicaid Services......